Regulation - Asia-Pacific, Licensing

Filter

Current filters:

Asia-PacificLicensing

Popular Filters

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

05-12-2013

Revealing an earlier agreement yesterday, Israel’s Teva Pharmaceutical Industries and Japan’s largest…

Asia-PacificCopaxoneGlatiramer AcetateLicensingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

19-11-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform has been launched in Japan…

Asia-PacificFlutiformKyorin PharmaceuticalsLicensingPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Roche affiliate Chugai files for T-DM1 approval in Japan; gains rights to Afraxis compound

30-01-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

AfraxisAsia-PacificChugai PharmaceuticalGenentechGlobalLicensingOncologyPharmaceuticalProductionRegulationRocheT-DM1trastuzumab emtansine

Back to top